Zepsyre . Reviewing the Small Cell Lung Cancer Landscape in Light of Recent Data, with a Focus on Lurbinectedin's Phase 3 Program . Nueve Preguntas Claves al Dr. Jack West .

Q1.

There has been some movement in therapeutic approvals in SCLC recently. Can you walk me through how you are currently treating a new SCLC patient who comes to you?

Added By: j_admin

Q2.

How has Atezolizumab's inclusion in the NCCN guidelines for first line and maintenance changed your treatment approach? 

• How important is FDA approval vs. guideline inclusion?

Added By: j_admin

Q3.

How do you use and view nivolumab after FDA approval in light of the Checkmate 331 results?

Added By: j_admin

Q4.

What do you view as the most promising or exciting late stage program in SCLC currently?

Added By: j_admin

Q5.

With Atezolizumab moving into front line, many patients will now be receiving an I/O first. What does this do for the 2nd line landscape? How appealing is Topotecan in this setting at this point and what else would you look to use in these patients?

Added By: j_admin

Q6.

Lurbinectedin's monotherapy trial should be reading out in the first quarter of 2019. What is the ORR and DR response rates does it need to hit to keep you excited about the drug's prospects? How connected is the Monotherapy results to the ATLANTIS results in your mind or should we be looking more at safety and and tolerability in this first trial?

Added By: j_admin

Q7.

If IO is getting used in the front line setting, and in fact Nivo recenlty failed in the second line, what do you think will become standard of care in 2nd line assuming phase II data substantively convinces of benefit or is confirmed in phase III? Will IO after IO progression be an option?

Added By: usercdb8aa0e

Q8.

Why do you think there has been such a disparity in terms of agents working in Non-small cell lung cancer treatments recently vs small cell? How does Lurbi’s understood mechanism fit into this framework?

Added By: j_admin

Q9.

Dr. West, thank you for the presentation. Assuming that the Lubinectedin is approved, where do you project that the drug would be used in the context of Nivo, surgery, and chemo/radiation?  Second question is given that Nivo's efficacy is underwhelming, do you ever use Nivo and if so in what context? Do you ever use genomics testing for small cell lung cancer despite that the PDL1/PD1 not correlating with survival?